Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis

Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole‐body tum...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of medical genetics. Part A Vol. 164A; no. 6; pp. 1431 - 1437
Main Authors Merker, Vanessa L., Bredella, Miriam A., Cai, Wenli, Kassarjian, Ara, Harris, Gordon J., Muzikansky, Alona, Nguyen, Rosa, Mautner, Victor F., Plotkin, Scott R.
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.06.2014
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text
ISSN1552-4825
1552-4833
1552-4833
DOI10.1002/ajmg.a.36466

Cover

Abstract Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole‐body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF‐36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole‐body MRI. One‐sample t‐tests were used to compare norm‐based SF‐36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease‐specific clinical variable were used to relate whole‐body tumor volume to QOL scales. Two hundred forty‐five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF‐36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF‐36 bodily pain subscale (rho = −0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF‐36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor‐focused therapies such as surgery by including psychosocial interventions. © 2014 Wiley Periodicals, Inc.
AbstractList Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho = -0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions.Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho = -0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions.
Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole‐body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF‐36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole‐body MRI. One‐sample t‐tests were used to compare norm‐based SF‐36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease‐specific clinical variable were used to relate whole‐body tumor volume to QOL scales. Two hundred forty‐five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF‐36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF‐36 bodily pain subscale (rho = −0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF‐36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor‐focused therapies such as surgery by including psychosocial interventions. © 2014 Wiley Periodicals, Inc.
Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho = -0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions.
Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho=-0.287, P=0.04) and VAS (rho=0.34, P=0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P=0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions. © 2014 Wiley Periodicals, Inc. [PUBLICATION ABSTRACT]
Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho=-0.287, P=0.04) and VAS (rho=0.34, P=0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P=0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions. copyright 2014 Wiley Periodicals, Inc.
Author Plotkin, Scott R.
Merker, Vanessa L.
Nguyen, Rosa
Cai, Wenli
Harris, Gordon J.
Bredella, Miriam A.
Mautner, Victor F.
Kassarjian, Ara
Muzikansky, Alona
Author_xml – sequence: 1
  givenname: Vanessa L.
  surname: Merker
  fullname: Merker, Vanessa L.
  organization: Department of Neurology and Cancer Center, Massachusetts General Hospital, Massachusetts, Boston
– sequence: 2
  givenname: Miriam A.
  surname: Bredella
  fullname: Bredella, Miriam A.
  organization: Department of Radiology, Massachusetts General Hospital, Massachusetts, Boston
– sequence: 3
  givenname: Wenli
  surname: Cai
  fullname: Cai, Wenli
  organization: Department of Radiology, Massachusetts General Hospital, Massachusetts, Boston
– sequence: 4
  givenname: Ara
  surname: Kassarjian
  fullname: Kassarjian, Ara
  organization: Department of Radiology, Corades, S.L., Majadahonda, Spain
– sequence: 5
  givenname: Gordon J.
  surname: Harris
  fullname: Harris, Gordon J.
  organization: Department of Radiology, Massachusetts General Hospital, Massachusetts, Boston
– sequence: 6
  givenname: Alona
  surname: Muzikansky
  fullname: Muzikansky, Alona
  organization: Biostatistics Center, Massachusetts General Hospital, Massachusetts, Boston
– sequence: 7
  givenname: Rosa
  surname: Nguyen
  fullname: Nguyen, Rosa
  organization: Department of Pediatrics, University of Maryland, Baltimore, Maryland
– sequence: 8
  givenname: Victor F.
  surname: Mautner
  fullname: Mautner, Victor F.
  organization: Department of Neurology, University Hospital, Hamburg, Germany
– sequence: 9
  givenname: Scott R.
  surname: Plotkin
  fullname: Plotkin, Scott R.
  email: Correspondence to:Scott R. Plotkin, M.D., Ph.D., Yawkey 9E, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114., splotkin@partners.org
  organization: Department of Neurology and Cancer Center, Massachusetts General Hospital, Massachusetts, Boston
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24664633$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1v0zAYhyM0xLbCjTOyxIVDUxx_JTlWFRTQ-NAE4mg5zhvq4tiZ7ajrf0-6rjtMAnHyK-t5ftL7_i6zM-cdZNnLAi8KjMlbte1_LdSCCibEk-yi4JzkrKL07GEm_Dy7jHGLMcW8FM-yczKxTFB6kd1eg1XJeBc3ZkANpB2AQ7uNt5A3vt2jNPY-oGYMLbg50tY4o5VFwwacT_sB5ki5Ft2Mypq0R75D1nSAjEPDFAsuRbQzaYMcjMF3pgm-V8lHE59nTztlI7y4f2fZj_fvvq8-5Fdf1x9Xy6tcs5KKXFEhikqLsiEcTz8t60pcs6JSNdW8rjUVQAouVFkRjXkjSKVVyVrWAK1boekse3PMHYK_GSEm2ZuowVrlwI9RFpzUNadFXf8PShlmdLruLHv9CN36MbhpkQNVlJRNiRP16p4amx5aOQTTq7CXp_NPADkCOvgYA3RSm3RXRwrKWFlgeehYHjqWSt51PEnzR9Ip9y84O-I7Y2H_T1YuP31eL09aftRMTHD7oKnwW4qSllz-_LKW365ZvWJrIiv6B8WRx_Y
CitedBy_id crossref_primary_10_1002_jmri_25236
crossref_primary_10_1002_ajmg_a_37987
crossref_primary_10_1186_s13550_024_01189_0
crossref_primary_10_1002_acn3_51386
crossref_primary_10_1097_SAP_0000000000000494
crossref_primary_10_1227_neu_0000000000002242
crossref_primary_10_1007_s10897_016_9939_8
crossref_primary_10_1093_noajnl_vdaa003
crossref_primary_10_1093_nop_npae084
crossref_primary_10_1177_17407745231209224
crossref_primary_10_2147_PHMT_S362679
crossref_primary_10_1097_SCS_0000000000004685
crossref_primary_10_1016_j_det_2019_05_015
crossref_primary_10_1212_WNL_0000000000002929
crossref_primary_10_1212_WNL_0000000000002927
crossref_primary_10_1093_neuonc_nou235
crossref_primary_10_1007_s11060_016_2314_7
crossref_primary_10_1093_neuonc_nov200
crossref_primary_10_1007_s00381_020_04754_9
crossref_primary_10_1038_nrdp_2017_4
crossref_primary_10_1007_s00256_024_04765_6
crossref_primary_10_1016_j_jacr_2015_06_003
crossref_primary_10_1212_WNL_0000000000201535
crossref_primary_10_1038_s41598_019_49705_w
crossref_primary_10_3389_fpubh_2024_1398803
crossref_primary_10_5209_PSIC_59173
crossref_primary_10_1016_j_ejim_2014_04_004
crossref_primary_10_1097_SCS_0000000000006015
crossref_primary_10_1016_j_spen_2024_101172
crossref_primary_10_1007_s10880_018_9584_5
crossref_primary_10_1093_noajnl_vdz045
crossref_primary_10_3171_CASE21176
crossref_primary_10_1186_s12883_019_1338_y
crossref_primary_10_1093_noajnl_vdaa095
crossref_primary_10_1097_MAO_0000000000001019
crossref_primary_10_1111_jdv_18140
crossref_primary_10_1148_radiol_2016160293
crossref_primary_10_1007_s13235_024_00609_z
crossref_primary_10_1177_0883073816666736
crossref_primary_10_1007_s00256_019_03290_1
crossref_primary_10_1007_s11916_024_01283_x
crossref_primary_10_2147_JPR_S287603
crossref_primary_10_1080_13651501_2021_1921217
crossref_primary_10_1097_MD_0000000000009717
crossref_primary_10_14730_aaps_2020_02187
Cites_doi 10.1002/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8
10.1002/1098-2779(2000)6:2<117::AID-MRDD5>3.0.CO;2-X
10.1111/j.1749-4486.2010.02176.x
10.1159/000337548
10.1080/87565641.2012.695831
10.1177/1087054712450749
10.1371/journal.pone.0035711
10.1148/radiol.2503080700
10.1001/archderm.137.11.1421
10.1212/01.WNL.0000163982.78900.AD
10.1212/01.wnl.0000179303.72345.ce
10.1212/01.WNL.0000035638.74084.F4
10.1097/00129492-200501000-00016
10.1002/ajmg.a.31422
10.1159/000187594
10.1634/theoncologist.2012-0162
10.7326/0003-4819-113-1-39
ContentType Journal Article
Copyright 2014 Wiley Periodicals, Inc.
Copyright_xml – notice: 2014 Wiley Periodicals, Inc.
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
8FD
FR3
K9.
P64
RC3
7X8
DOI 10.1002/ajmg.a.36466
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
Genetics Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Genetics Abstracts
Technology Research Database
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Calcium & Calcified Tissue Abstracts
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Genetics Abstracts
Genetics Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1552-4833
EndPage 1437
ExternalDocumentID 3296098901
24664633
10_1002_ajmg_a_36466
AJMGA36466
ark_67375_WNG_PR49C4G2_8
Genre article
Research Support, U.S. Gov't, Non-P.H.S
Journal Article
GrantInformation_xml – fundername: Department of Defense Neurofibromatosis Research Program
  funderid: NF050202
GroupedDBID ---
.55
.GA
.Y3
05W
0R~
10A
1L6
1OB
1OC
23M
31~
33P
3O-
4.4
50Y
51W
51X
52M
52N
52O
52P
52S
52T
52W
52X
53G
5GY
5VS
66C
6P2
702
7PT
8-1
8-4
8-5
8UM
930
A03
AAEVG
AAHQN
AAMMB
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABEML
ABIJN
ABJNI
ACAHQ
ACBWZ
ACCZN
ACFBH
ACGFO
ACGFS
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEFGJ
AEIGN
AEIMD
AENEX
AEUYR
AEYWJ
AFBPY
AFFPM
AFGKR
AFWVQ
AFZJQ
AGHNM
AGQPQ
AGXDD
AGYGG
AHBTC
AIDQK
AIDYY
AITYG
AIURR
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
BDRZF
BFHJK
BRXPI
BSCLL
BY8
C45
CO8
CS3
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
EBD
EBS
EJD
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
GNP
GODZA
HBH
HF~
HGLYW
HHY
HHZ
HVGLF
IX1
JPC
KD1
KQQ
L7B
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
OIG
OVD
P2W
P4D
QB0
QRW
ROL
RX1
RYL
SUPJJ
SV3
TEORI
UB1
V2E
WIH
WIK
WJL
WQJ
X7M
XG1
XV2
AAHHS
AAYXX
ACCFJ
ADZOD
AEEZP
AEQDE
AIWBW
AJBDE
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TK
8FD
FR3
K9.
P64
RC3
7X8
ID FETCH-LOGICAL-c4736-a36618c67b250473d4f709418a93c599c36e2156a782c05b628ca74d4be39d6c3
IEDL.DBID DR2
ISSN 1552-4825
1552-4833
IngestDate Fri Sep 05 08:14:43 EDT 2025
Fri Sep 05 06:43:26 EDT 2025
Wed Aug 13 06:43:43 EDT 2025
Thu Apr 03 07:09:16 EDT 2025
Thu Apr 24 23:02:45 EDT 2025
Tue Jul 01 00:44:58 EDT 2025
Sun Sep 21 06:21:48 EDT 2025
Sun Sep 21 06:20:55 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords pain
nerve sheath tumor
whole-body MRI
schwannomatosis
neurofibromatosis 2
quality of life
neurofibromatosis 1
SF-36
Language English
License http://onlinelibrary.wiley.com/termsAndConditions#vor
2014 Wiley Periodicals, Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4736-a36618c67b250473d4f709418a93c599c36e2156a782c05b628ca74d4be39d6c3
Notes ark:/67375/WNG-PR49C4G2-8
Department of Defense Neurofibromatosis Research Program - No. NF050202
istex:AD4AC3C5D68AF2868E3D3D9BD3E979D404034985
ArticleID:AJMGA36466
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://nrs.harvard.edu/urn-3:HUL.InstRepos:33788496
PMID 24664633
PQID 1521734319
PQPubID 2028748
PageCount 7
ParticipantIDs proquest_miscellaneous_1529953199
proquest_miscellaneous_1523404348
proquest_journals_1521734319
pubmed_primary_24664633
crossref_citationtrail_10_1002_ajmg_a_36466
crossref_primary_10_1002_ajmg_a_36466
wiley_primary_10_1002_ajmg_a_36466_AJMGA36466
istex_primary_ark_67375_WNG_PR49C4G2_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2014
PublicationDateYYYYMMDD 2014-06-01
PublicationDate_xml – month: 06
  year: 2014
  text: June 2014
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
PublicationTitle American journal of medical genetics. Part A
PublicationTitleAlternate Am. J. Med. Genet
PublicationYear 2014
Publisher Blackwell Publishing Ltd
Wiley Subscription Services, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: Wiley Subscription Services, Inc
References Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG. 2010b. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299.
MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. 2005. Diagnostic criteria for schwannomatosis. Neurology 64:1838-1845.
Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. 2009. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole-body MR images. Radiology 250:665-673.
Pride NA, Payne JM, North KN. 2012. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol 37:590-600.
Lu-Emerson C, Plotkin S. 2009a. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47-E53.
Lu-Emerson C, Plotkin S. 2009b. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81-E86.
Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. 1990. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39-52.
Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. 2001. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases. Arch Dermatol 137:1421-1425.
Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DG. 2010a. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299.
Kayl AE, Moore BD III. 2000. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 6:117-124.
Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044.
Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. 2012. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7:e35711.
Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. 2005. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93-97.
Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. 2006. Impact of neurofibromatosis 1 on quality of life: A cross-sectional study of 176 American cases. Am J Med Genet Part A 140A:1893-1898.
Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D. 2009. Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215-220.
Granstrom S, Langenbruch A, Augustin M, Mautner VF. 2012. Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image. Dermatology 224:160-167.
Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. 2007. User's manual for the Sf-36v2 health survey, 2nd edition. Lincoln, RI: QualityMetric Incorporated.
Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6.
Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. 2012. Clinical features of schwannomatosis: A retrospective analysis of 87 patients. Oncologist 17:1317-1322.
Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. 2002. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765.
Mautner VF, Granstrom S, Leark RA. 2012. Impact of ADHD in adults with neurofibromatosis type 1: Associated psychological and social problems. J Atten Disord [Epub ahead of print].
2006; 140A
2002; 59
2000; 6
2012
2009a; 6
2009b; 6
2010a; 35
2011
1999; 89
2005; 64
2007
2005; 65
2009; 250
2012; 17
2012; 37
2005; 26
2012; 224
2009; 218
1990; 113
2012; 7
2010b; 35
2001; 137
e_1_2_6_21_1
Ware JE (e_1_2_6_23_1) 2007
e_1_2_6_20_1
Lu‐Emerson C (e_1_2_6_11_1) 2009; 6
e_1_2_6_9_1
e_1_2_6_8_1
e_1_2_6_19_1
e_1_2_6_5_1
e_1_2_6_4_1
e_1_2_6_7_1
e_1_2_6_6_1
e_1_2_6_13_1
Ware JE (e_1_2_6_22_1) 2011
Lu‐Emerson C (e_1_2_6_10_1) 2009; 6
e_1_2_6_14_1
e_1_2_6_24_1
e_1_2_6_3_1
e_1_2_6_2_1
e_1_2_6_12_1
e_1_2_6_17_1
e_1_2_6_18_1
e_1_2_6_15_1
e_1_2_6_16_1
References_xml – reference: Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. 2012. Clinical features of schwannomatosis: A retrospective analysis of 87 patients. Oncologist 17:1317-1322.
– reference: Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. 2007. User's manual for the Sf-36v2 health survey, 2nd edition. Lincoln, RI: QualityMetric Incorporated.
– reference: Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. 2006. Impact of neurofibromatosis 1 on quality of life: A cross-sectional study of 176 American cases. Am J Med Genet Part A 140A:1893-1898.
– reference: Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. 2009. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole-body MR images. Radiology 250:665-673.
– reference: Kayl AE, Moore BD III. 2000. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 6:117-124.
– reference: Lu-Emerson C, Plotkin S. 2009a. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47-E53.
– reference: Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6.
– reference: Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. 2012. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7:e35711.
– reference: Granstrom S, Langenbruch A, Augustin M, Mautner VF. 2012. Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image. Dermatology 224:160-167.
– reference: Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG. 2010b. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299.
– reference: Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. 1990. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39-52.
– reference: Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044.
– reference: Lu-Emerson C, Plotkin S. 2009b. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81-E86.
– reference: Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. 2005. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93-97.
– reference: Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. 2002. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765.
– reference: Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DG. 2010a. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299.
– reference: Pride NA, Payne JM, North KN. 2012. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol 37:590-600.
– reference: Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D. 2009. Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215-220.
– reference: Mautner VF, Granstrom S, Leark RA. 2012. Impact of ADHD in adults with neurofibromatosis type 1: Associated psychological and social problems. J Atten Disord [Epub ahead of print].
– reference: MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. 2005. Diagnostic criteria for schwannomatosis. Neurology 64:1838-1845.
– reference: Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. 2001. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases. Arch Dermatol 137:1421-1425.
– year: 2012
  article-title: Impact of ADHD in adults with neurofibromatosis type 1: Associated psychological and social problems
  publication-title: J Atten Disord
– year: 2011
– volume: 113
  start-page: 39
  year: 1990
  end-page: 52
  article-title: NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update
  publication-title: Ann Intern Med
– volume: 59
  start-page: 1759
  year: 2002
  end-page: 1765
  article-title: Evaluation of clinical diagnostic criteria for neurofibromatosis 2
  publication-title: Neurology
– volume: 250
  start-page: 665
  year: 2009
  end-page: 673
  article-title: Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole‐body MR images
  publication-title: Radiology
– volume: 35
  start-page: 291
  year: 2010b
  end-page: 299
  article-title: The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form‐36
  publication-title: Clin Otolaryngol
– volume: 218
  start-page: 215
  year: 2009
  end-page: 220
  article-title: Health‐related quality of life in patients with neurofibromatosis type 1
  publication-title: Dermatology
– volume: 137
  start-page: 1421
  year: 2001
  end-page: 1425
  article-title: Quality‐of‐life impairment in neurofibromatosis type 1: A cross‐sectional study of 128 cases
  publication-title: Arch Dermatol
– volume: 89
  start-page: 1
  year: 1999
  end-page: 6
  article-title: Epidemiology of neurofibromatosis type 1
  publication-title: Am J Med Genet
– volume: 6
  start-page: 117
  year: 2000
  end-page: 124
  article-title: Behavioral phenotype of neurofibromatosis, type 1
  publication-title: Ment Retard Dev Disabil Res Rev
– volume: 35
  start-page: 291
  year: 2010a
  end-page: 299
  article-title: The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form‐36
  publication-title: Clin Otolaryngol
– volume: 37
  start-page: 590
  year: 2012
  end-page: 600
  article-title: The impact of ADHD on the cognitive and academic functioning of children with NF1
  publication-title: Dev Neuropsychol
– volume: 6
  start-page: E81
  year: 2009b
  end-page: E86
  article-title: The neurofibromatoses. Part 2: NF2 and schwannomatosis
  publication-title: Rev Neurol Dis
– volume: 224
  start-page: 160
  year: 2012
  end-page: 167
  article-title: Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image
  publication-title: Dermatology
– year: 2007
– volume: 140A
  start-page: 1893
  year: 2006
  end-page: 1898
  article-title: Impact of neurofibromatosis 1 on quality of life: A cross‐sectional study of 176 American cases
  publication-title: Am J Med Genet Part A
– volume: 26
  start-page: 93
  year: 2005
  end-page: 97
  article-title: Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10‐year period: higher incidence than previously thought
  publication-title: Otol Neurotol
– volume: 7
  start-page: e35711
  year: 2012
  article-title: Quantitative assessment of whole‐body tumor burden in adult patients with neurofibromatosis
  publication-title: PLoS ONE
– volume: 6
  start-page: E47
  year: 2009a
  end-page: E53
  article-title: The neurofibromatoses. Part 1: NF1
  publication-title: Rev Neurol Dis
– volume: 64
  start-page: 1838
  year: 2005
  end-page: 1845
  article-title: Diagnostic criteria for schwannomatosis
  publication-title: Neurology
– volume: 17
  start-page: 1317
  year: 2012
  end-page: 1322
  article-title: Clinical features of schwannomatosis: A retrospective analysis of 87 patients
  publication-title: Oncologist
– volume: 65
  start-page: 1037
  year: 2005
  end-page: 1044
  article-title: The nature and frequency of cognitive deficits in children with neurofibromatosis type 1
  publication-title: Neurology
– ident: e_1_2_6_5_1
  doi: 10.1002/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8
– ident: e_1_2_6_8_1
  doi: 10.1002/1098-2779(2000)6:2<117::AID-MRDD5>3.0.CO;2-X
– ident: e_1_2_6_17_1
  doi: 10.1111/j.1749-4486.2010.02176.x
– ident: e_1_2_6_6_1
  doi: 10.1159/000337548
– ident: e_1_2_6_20_1
  doi: 10.1080/87565641.2012.695831
– ident: e_1_2_6_16_1
  doi: 10.1111/j.1749-4486.2010.02176.x
– ident: e_1_2_6_13_1
  doi: 10.1177/1087054712450749
– volume: 6
  start-page: E81
  year: 2009
  ident: e_1_2_6_11_1
  article-title: The neurofibromatoses. Part 2: NF2 and schwannomatosis
  publication-title: Rev Neurol Dis
– ident: e_1_2_6_21_1
– ident: e_1_2_6_19_1
  doi: 10.1371/journal.pone.0035711
– volume-title: User's manual for the Sf‐36v2 health survey
  year: 2011
  ident: e_1_2_6_22_1
– ident: e_1_2_6_3_1
  doi: 10.1148/radiol.2503080700
– ident: e_1_2_6_24_1
  doi: 10.1001/archderm.137.11.1421
– ident: e_1_2_6_12_1
  doi: 10.1212/01.WNL.0000163982.78900.AD
– ident: e_1_2_6_7_1
  doi: 10.1212/01.wnl.0000179303.72345.ce
– ident: e_1_2_6_2_1
  doi: 10.1212/01.WNL.0000035638.74084.F4
– volume-title: User's manual for the Sf‐36v2 health survey
  year: 2007
  ident: e_1_2_6_23_1
– ident: e_1_2_6_4_1
  doi: 10.1097/00129492-200501000-00016
– ident: e_1_2_6_18_1
  doi: 10.1002/ajmg.a.31422
– ident: e_1_2_6_9_1
  doi: 10.1159/000187594
– volume: 6
  start-page: E47
  year: 2009
  ident: e_1_2_6_10_1
  article-title: The neurofibromatoses. Part 1: NF1
  publication-title: Rev Neurol Dis
– ident: e_1_2_6_14_1
  doi: 10.1634/theoncologist.2012-0162
– ident: e_1_2_6_15_1
  doi: 10.7326/0003-4819-113-1-39
SSID ssj0030576
Score 2.2821622
Snippet Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1431
SubjectTerms Adolescent
Adult
Aged
Aged, 80 and over
Attention Deficit Disorder with Hyperactivity - diagnosis
Attention Deficit Disorder with Hyperactivity - psychology
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Nerve Sheath Neoplasms - complications
Nerve Sheath Neoplasms - psychology
nerve sheath tumor
Neurilemmoma - complications
Neurilemmoma - psychology
Neurofibromatoses - complications
Neurofibromatoses - psychology
neurofibromatosis 1
Neurofibromatosis 1 - diagnostic imaging
Neurofibromatosis 1 - pathology
Neurofibromatosis 1 - psychology
neurofibromatosis 2
Neurofibromatosis 2 - diagnostic imaging
Neurofibromatosis 2 - pathology
Neurofibromatosis 2 - psychology
pain
Pain - complications
Pain Measurement
quality of life
Quality of Life - psychology
Radiography
schwannomatosis
SF-36
Skin Neoplasms - complications
Skin Neoplasms - psychology
Surveys and Questionnaires
Tumor Burden
whole-body MRI
Young Adult
Title Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis
URI https://api.istex.fr/ark:/67375/WNG-PR49C4G2-8/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fajmg.a.36466
https://www.ncbi.nlm.nih.gov/pubmed/24664633
https://www.proquest.com/docview/1521734319
https://www.proquest.com/docview/1523404348
https://www.proquest.com/docview/1529953199
Volume 164A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZQEYgLlPIXKMhIwIV6m8SOEx9XFd2q0laooqI3yz9JWdom1WZXsD3xCH3GPkk9jjdQBJXgZinjyHZm7C_jmW8QemNtmqqkMkSkmhGmWEG0iSkptaDCnUA6ziF3eLzHdw7Y7mF2GBxukAvT8UP0DjewDL9fg4Er3W7-JA1VX0-PBmpAOePAuJ24BmCi_Z49ymmyry0HJGOEuT-hEPfuum_-2vnaiXQbFvf7n-DmdfTqj5_tB0guB95FnRwP5jM9MOe_cTr-_8xW0f2ATPGwU6WH6FZZr6E7Xa3KxRq6Ow638I_QeR9B92VyhkOkF_4GlXYvf1zoxi7wbH7aTLH2ORIbeJl-iSGgrAGv7wZWtcVdRucCNxU-mVQlntQ48Ly2GBzE2LNtVm4yjQPWTTtpH6OD7Q-ftnZIqOFADMspJ4o6AFAYnmvgSsupZVXu_iiTQglqMiEM5aVDHVw5pGLiTPO0MCpnlumSCssNfYJW6qYunyHsoKdJKs-fr1hZUV0lMbXGuq0-E0VsIvR--R2lCQTnUGfjRHbUzKmEhZVK-oWN0Nte-qwj9viL3DuvEr2Qmh5DMFyeyc97I_lxn4ktNkplEaH1pc7IsA-0EtBRTh1IExF63T92FgzXMqoum7mXocBxxIobZYSA7dK952mnj_2AUqgQwCmNEPFadeN05HB3PBr65vN_lH-B7jm0yLo4uXW0MpvOy5cOkc30K293VxuVMYg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BK6AXHuXRlAJGAi5tttnYceLjqqK7lO4KVa3ozdhO0i5tk2ofKtsTP4HfyC_B42QDRVAJcYuUcWQ7M_bn8cw3AK_SNAxVOze-CDXzmWKJr01A_UwLKuwOpIMYc4f7A947YDuH0WFd5xRzYSp-iMbhhpbh1ms0cHRIb_5kDVWfz45aqkU54_wmLLorOkRFew1_lNVlV10OacZ8Zs9CdeS7bb_5a-sre9IiTu-XPwHOq_jVbUDb9-DTvOtV3MlJazrRLXP5G6vjf4ztPtytwSnpVNr0AG5kxTLcqspVzpbhdr--iH8Il00Q3fHwnNTBXuQCi-1-__pNl-mMTKZn5YholyaxQeYZmARjykp0_G4QVaSkSuqckTInp8M8I8OC1FSvY4I-YuIIN3M7mtJi63I8HD-Cg-23-1s9vy7j4BsWU-4rajFAYniskS4tpinLY3uobCdKUBMJYSjPLPDgyoIVE0Sah4lRMUuZzqhIuaGPYaEoi2wFiEWfpp07Cn3FspzqvB3Q1KR2tY9EEhgP1uc_Upqa4xxLbZzKip05lDixUkk3sR68bqTPK26Pv8i9cTrRCKnRCcbDxZH8OOjKD3tMbLFuKBMP1uZKI-ulYCwRIMXU4jThwcvmtTVivJlRRVZOnQxFmiOWXCsjBK6Y9jtPKoVsOhRikQBOqQe-U6trhyM7O_1uxz2u_qP8C7jT2-_vyt13g_dPYcmCR1aFza3BwmQ0zZ5ZgDbRz50R_gAcgzWm
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BKyouPMorUMBIwIVmm429TnxcFXZLYVdVRUVvlh8J3T6S1T4E2xM_gd_IL8HjZANFUAlukTKObGc889me-QbgubVxrNq5CUWsWcgUS0NtIhpmWlDhPJCOEswdHgz5zgHbPewc1gdumAtT8UM0B264Mry9xgU-tvnWT9JQdXz2qaValDPOr8Iq485TIijab-ijnCr74nLIMhYytxWqA99d-61fW19wSas4u1_-hDcvwlfvf3o3QS57XoWdnLTmM90y57-ROv7_0G7BjRqakm6lS7fhSlasw7WqWOViHdYG9TX8HThvQuiORmNSh3qRz1hq9_vXb7q0CzKbn5UTon2SxCZZ5l8SjCgr8dh3k6jCkiqlc0HKnJyO8oyMClITvU4JnhATT7eZu8GUDlmX09H0Lhz03nzY3gnrIg6hYQnloaIOAaSGJxrJ0hJqWZ64LWU7VYKajhCG8szBDq4cVDFRR_M4NSphlumMCssNvQcrRVlkD4A47GnauSfQVyzLqc7bEbXGOlvfEWlkAni1_I_S1AznWGjjVFbczLHEiZVK-okN4EUjPa6YPf4i99KrRCOkJicYDZd05MdhX-7tM7HN-rFMA9hY6oysDcFUIjxKqENpIoBnzWu3hPFeRhVZOfcyFEmOWHqpjBBoL9137lf62HQoxhIBnNIAQq9Vlw5HdncH_a5_fPiP8k9hbe91T75_O3z3CK475MiqmLkNWJlN5tljh85m-olfgj8AVNc0VQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+whole-body+tumor+burden%2C+clinical+phenotype%2C+and+quality+of+life+in+patients+with+neurofibromatosis&rft.jtitle=American+journal+of+medical+genetics.+Part+A&rft.au=Merker%2C+Vanessa+L&rft.au=Bredella%2C+Miriam+A&rft.au=Cai%2C+Wenli&rft.au=Kassarjian%2C+Ara&rft.date=2014-06-01&rft.eissn=1552-4833&rft.volume=164A&rft.issue=6&rft.spage=1431&rft_id=info:doi/10.1002%2Fajmg.a.36466&rft_id=info%3Apmid%2F24664633&rft.externalDocID=24664633
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-4825&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-4825&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-4825&client=summon